Bernard Luke FLYNN,Dharam PAUL,Andrew John HARVEY,Vasu V SETHURAMAN,Raymond E FORSLUND,Song XUE,Rob LIVINGSTON,Ahmad HASHASH
申请号：
HK16108260.8
公开号：
HK1220191A
申请日:
2016.07.14
申请国别(地区):
HK
年份:
2017
代理人:
摘要：
The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.
